MedTrace Logo

Atorvastatin Before Prostatectomy and Prostate Cancer

NCT01821404 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2018-05-07

No results posted yet for this study

Summary

This single-center, randomized, double-blind trial assesses the impact of short-term atorvastatin administration on proliferation activity, apoptotic rate and histological inflammation in prostate tissue.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Atorvastatin

Capsules including 80 mg of atorvastatin

DRUG

Placebo

Similar capsules as in the atorvastatin arm, but without the active ingredient

Sponsors & Collaborators

  • Tampere University

    collaborator OTHER

  • Fimlab laboratories

    collaborator UNKNOWN

  • University of Eastern Finland

    collaborator OTHER

  • Finnish Cultural Foundation

    collaborator OTHER

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Teemu J Murtola, M.D., Ph.D. · Tampere University

  • Teuvo LJ Tammela, M.D., Ph.D. · Tampere University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01821404 on ClinicalTrials.gov